Clinical trials: Residual Kidney Function
End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
Empagliflozin, a new class of diabetes medication, has demonstrated a reduction in renal function decline among patients with chronic kidney disease, regardless of their diabetes status.
- Conditions
- End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication, Sodium-glucose Cotransporter-2 Inhibitor, Residual Kidney Function
- Trial name
- EMPIRIC-PD (NCT06483074)
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 48 people
- Sponsor
- Chinese University of Hong Kong
Peritoneal Dialysis Complication, End Stage Kidney Disease
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).
- Conditions
- Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors, Kidney Dysfunction
- Trial name
- CANARY (NCT05715814)
- Testing
- Empagliflozin 25 MG
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Peritoneal Dialysis Complication, Residual Kidney Function
Incremental PD With Single Icodextrin Exchange
Objectives: To investigate the efficacy and safety of single daily icodextrin exchange for initiation of incremental peritoneal dialysis (PD). Subjects: Seventy-two incident PD patients.
- Conditions
- Peritoneal Dialysis Complication, Residual Kidney Function, Survival, Health-related Quality of Life
- Trial name
- NCT06119373
- Testing
- Single daily icodextrin exchange, Conventional PD group
- Volunteers
- 72 people
- Sponsor
- RenJi Hospital
Loss of Residual Renal Function, Technique Failure in Peritoneal Dialysis
Peritonitis and Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients
The primary objective is to analyze peritonitis rate and peritonitis bacteriology as risk factors for loss of residual renal function, technique failure and mortality in chronic kidney disease patients.
- Trial name
- NCT01977716
- Where
- Mexico
- Volunteers
- 350 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico